Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
A Phase 1 Single and Multiple Ascending Dose and Drug Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Sponsor: MBX Biosciences
A PHASE1 clinical study on Postbariatric Hypoglycemia, this trial is completed. The trial is conducted by MBX Biosciences and has accumulated 8 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Dec 2023 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MBX Biosciences
- ProSciento, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .